{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:30:44Z","timestamp":1779877844433,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gusu Talent Program","award":["GSWS2022069"],"award-info":[{"award-number":["GSWS2022069"]}]},{"name":"China Medical and Health Development Foundation","award":["202427"],"award-info":[{"award-number":["202427"]}]},{"DOI":"10.13039\/501100018556","name":"Suzhou Science and Technology Project","doi-asserted-by":"crossref","award":["SKJYD2021172"],"award-info":[{"award-number":["SKJYD2021172"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018556","name":"Suzhou Science and Technology Project","doi-asserted-by":"crossref","award":["SKJYD2021171"],"award-info":[{"award-number":["SKJYD2021171"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018556","name":"Suzhou Science and Technology Project","doi-asserted-by":"crossref","award":["SKJYD2021170"],"award-info":[{"award-number":["SKJYD2021170"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jiangsu Pharmaceutical Association Hospital Pharmacy Research Project","award":["H202109"],"award-info":[{"award-number":["H202109"]}]},{"name":"Jiangsu Pharmaceutical Association Hospital Pharmacy Research Project","award":["A202228"],"award-info":[{"award-number":["A202228"]}]},{"name":"Jiangsu Research Hospital Association for Precision Medication","award":["JY202203"],"award-info":[{"award-number":["JY202203"]}]},{"name":"Jiangsu Research Hospital Association for Precision Medication","award":["JY202204"],"award-info":[{"award-number":["JY202204"]}]},{"name":"Jiangsu Research Hospital Association for Precision Medication","award":["JY202212"],"award-info":[{"award-number":["JY202212"]}]},{"name":"Suzhou Pharmaceutical Association Hospital Pharmacy Research Project","award":["Syhky202312"],"award-info":[{"award-number":["Syhky202312"]}]},{"name":"Suzhou Pharmaceutical Association Hospital Pharmacy Research Project","award":["Syhky202313"],"award-info":[{"award-number":["Syhky202313"]}]},{"name":"Collaborative Innovation Project of Gusu School of Nanjing Medical University","award":["GSKY20240207"],"award-info":[{"award-number":["GSKY20240207"]}]},{"name":"Clinical Research Fund of Nanjing Medical University","award":["2024KF0237"],"award-info":[{"award-number":["2024KF0237"]}]},{"name":"Suzhou Special Technical Project for Diagnosis and Treatment of Key Clinical Diseases","award":["LCZX202112"],"award-info":[{"award-number":["LCZX202112"]}]},{"name":"Drug Safety Research Project by Adverse Drug Reactions Journal","award":["ADR2024MS21"],"award-info":[{"award-number":["ADR2024MS21"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-77768-x","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:02:13Z","timestamp":1730296933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A nomogram incorporating linezolid and metabolite concentrations for predicting linezolid induced thrombocytopenia in patients with renal impairment"],"prefix":"10.1038","volume":"14","author":[{"given":"Hanzhen","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufen","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"77768_CR1","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","volume":"379","author":"SS Magill","year":"2018","unstructured":"Magill, S. S. et al. Changes in prevalence of Health Care-Associated infections in U.S. hospitals. N Engl. J. Med. 379, 1732\u20131744 (2018).","journal-title":"N Engl. J. Med."},{"key":"77768_CR2","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil, A. C. et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical practice guidelines by the infectious diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 63, e61\u2013e111 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"77768_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/jcpt.13359","volume":"46","author":"Y Dai","year":"2021","unstructured":"Dai, Y. et al. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients. J. Clin. Pharm. Ther. 46, 807\u2013813 (2021).","journal-title":"J. Clin. Pharm. Ther."},{"key":"77768_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/jcpt.12762","volume":"44","author":"HS Kim","year":"2019","unstructured":"Kim, H. S., Lee, E., Cho, Y. J., Lee, Y. J. & Rhie, S. J. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study. J. Clin. Pharm. Ther. 44, 84\u201390 (2019).","journal-title":"J. Clin. Pharm. Ther."},{"key":"77768_CR5","doi-asserted-by":"publisher","first-page":"e00605","DOI":"10.1128\/AAC.00605-19","volume":"63","author":"RL Crass","year":"2019","unstructured":"Crass, R. L., Cojutti, P. G., Pai, M. P. & Pea, F. Reappraisal of linezolid dosing in renal impairment to improve safety. Antimicrob. Agents Chemother. 63, e00605-00619 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"77768_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bcp.14965","volume":"88","author":"C Shi","year":"2022","unstructured":"Shi, C. et al. Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 88, 464\u2013475 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"77768_CR7","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3855\/jidc.10859","volume":"13","author":"E Kaya K\u0131l\u0131\u00e7","year":"2019","unstructured":"Kaya K\u0131l\u0131\u00e7, E. et al. Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination. J. Infect. Developing Ctries. 13, 886\u2013891 (2019).","journal-title":"J. Infect. Developing Ctries."},{"key":"77768_CR8","doi-asserted-by":"publisher","first-page":"1292828","DOI":"10.3389\/fphar.2024.1292828","volume":"15","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. Prediction of risk factors for linezolid-induced thrombocytopenia based on neural network model. Front. Pharmacol. 15, 1292828 (2024).","journal-title":"Front. Pharmacol."},{"key":"77768_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bcpt.13123","volume":"124","author":"GW Choi","year":"2019","unstructured":"Choi, G. W. et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic. Clin. Pharmacol. Toxicol. 124, 228\u2013234 (2019).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"77768_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10096-019-03754-1","volume":"39","author":"J Cazavet","year":"2020","unstructured":"Cazavet, J. et al. Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 39, 527\u2013538 (2020).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"77768_CR11","doi-asserted-by":"crossref","unstructured":"Souza, E., Crass, R. L., Felton, J., Hanaya, K. & Pai, M. P. Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment. Antimicrob. Agents Chemother. 64 (2020).","DOI":"10.1128\/AAC.00027-20"},{"key":"77768_CR12","doi-asserted-by":"publisher","first-page":"641872","DOI":"10.3389\/fphar.2021.641872","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. UPLC-MS\/MS assay for the measurement of linezolid and its metabolite PNU-142300 in human serum and its application to patients with renal insufficiency. Front. Pharmacol. 12, 641872 (2021).","journal-title":"Front. Pharmacol."},{"key":"77768_CR13","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/jac\/dkad191","volume":"78","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia. J. Antimicrob. Chemother. 78, 1974\u20131981 (2023).","journal-title":"J. Antimicrob. Chemother."},{"key":"77768_CR14","doi-asserted-by":"publisher","first-page":"967311","DOI":"10.3389\/fpubh.2022.967311","volume":"10","author":"B Lin","year":"2022","unstructured":"Lin, B. et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front. Public. Health. 10, 967311 (2022).","journal-title":"Front. Public. Health"},{"key":"77768_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13756-024-01394-5","volume":"13","author":"G Zheng","year":"2024","unstructured":"Zheng, G. et al. Development of a risk prediction model for subsequent infection after colonization with carbapenem-resistant Enterobacterales: A retrospective cohort study. Antimicrob. Resist. Infect. Control 13, 46 (2024).","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"77768_CR16","unstructured":"U.S. Department of Health and Human Services. Guidance for industry pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing. (2010). https:\/\/www.fda.gov\/media\/78573\/download"},{"key":"77768_CR17","unstructured":"FDA. Highlights of prescribing information for ZYVOX. (2018). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206473s002lbl.pdf"},{"key":"77768_CR18","volume-title":"The Sanford guide to antimicrobial therapy","author":"DN Gilbert","year":"2020","unstructured":"Gilbert, D. N., Chambers, H. F. & Saag, M. S. The Sanford guide to antimicrobial therapy (Antimicrobial Therapy, Inc., 2020)."},{"key":"77768_CR19","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1177\/1060028018783498","volume":"52","author":"AD Rabon","year":"2018","unstructured":"Rabon, A. D., Fisher, J. P. & MacVane, S. H. Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater. Ann. Pharmacother 52, 1162\u20131164 (2018).","journal-title":"Ann. Pharmacother"},{"key":"77768_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.xphs.2021.02.014","volume":"110","author":"S Takahashi","year":"2021","unstructured":"Takahashi, S. et al. Classification tree analysis based on machine learning for predicting linezolid-induced thrombocytopenia. J. Pharm. Sci. 110, 2295\u20132300 (2021).","journal-title":"J. Pharm. Sci."},{"key":"77768_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","volume":"22","author":"Y Hanai","year":"2016","unstructured":"Hanai, Y. et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J. Infect. Chemother. 22, 536\u2013542 (2016).","journal-title":"J. Infect. Chemother."},{"key":"77768_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11096-014-9961-6","volume":"36","author":"R Hirano","year":"2014","unstructured":"Hirano, R., Sakamoto, Y., Tachibana, N. & Ohnishi, M. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int. J. Clin. Pharm. 36, 795\u2013799 (2014).","journal-title":"Int. J. Clin. Pharm."},{"key":"77768_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/phar.2719","volume":"42","author":"N Sakurai","year":"2022","unstructured":"Sakurai, N. et al. Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients. Pharmacotherapy. 42, 707\u2013715 (2022).","journal-title":"Pharmacotherapy"},{"key":"77768_CR24","doi-asserted-by":"crossref","unstructured":"Wu, F. et al. Dosage strategy of linezolid according to the trough concentration target and renal function in chinese critically ill patients. Front. Pharmacol. 13 (2022).","DOI":"10.3389\/fphar.2022.844567"},{"key":"77768_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jfma.2020.06.011","volume":"120","author":"CN Cheng","year":"2021","unstructured":"Cheng, C. N. et al. Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions. J. Formos. Med. Assoc. 120, 466\u2013475 (2021).","journal-title":"J. Formos. Med. Assoc."},{"key":"77768_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40360-021-00479-w","volume":"22","author":"H Kawasuji","year":"2021","unstructured":"Kawasuji, H. et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol. Toxicol. 22, 13 (2021).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"77768_CR27","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/bcp.13262","volume":"83","author":"Y Tsuji","year":"2017","unstructured":"Tsuji, Y. et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br. J. Clin. Pharmacol. 83, 1758\u20131772 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"77768_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijantimicag.2010.10.001","volume":"37","author":"D Pascoalinho","year":"2011","unstructured":"Pascoalinho, D., Vilas, M. J., Coelho, L. & Moreira, P. Linezolid-related immune-mediated severe thrombocytopenia. Int. J. Antimicrob. Agents. 37, 88\u201389 (2011).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"77768_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1345\/aph.1C361","volume":"37","author":"WB Bernstein","year":"2003","unstructured":"Bernstein, W. B., Trotta, R. F., Rector, J. T., Tjaden, J. A. & Barile, A. J. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann. Pharmacother. 37, 517\u2013520 (2003).","journal-title":"Ann. Pharmacother"},{"key":"77768_CR30","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1128\/AAC.01885-13","volume":"58","author":"LM Boak","year":"2014","unstructured":"Boak, L. M. et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob. Agents Chemother. 58, 2334\u20132343 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"77768_CR31","doi-asserted-by":"publisher","first-page":"844567","DOI":"10.3389\/fphar.2022.844567","volume":"13","author":"F Wu","year":"2022","unstructured":"Wu, F. et al. Dosage strategy of linezolid according to the trough concentration target and renal function in chinese critically ill patients. Front. Pharmacol. 13, 844567 (2022).","journal-title":"Front. Pharmacol."},{"key":"77768_CR32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1021\/ci1003834","volume":"51","author":"P Crivori","year":"2011","unstructured":"Crivori, P., Pennella, G., Magistrelli, M., Grossi, P. & Giusti, A. M. Predicting myelosuppression of drugs from in silico models. J. Chem. Inf. Model. 51, 434\u2013445 (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"77768_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/ejhpharm-2022-003258","volume":"31","author":"Y Qin","year":"2024","unstructured":"Qin, Y., Chen, Z., Gao, S., Shen, Y. & Ye, Y. Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients. Eur. J. Hosp. Pharm. 31, 94\u2013100 (2024).","journal-title":"Eur. J. Hosp. Pharm."},{"key":"77768_CR34","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jiac.2022.05.004","volume":"28","author":"I Maray","year":"2022","unstructured":"Maray, I. et al. Linezolid induced thrombocytopenia in critically ill patients: Risk factors and development of a machine learning-based prediction model. J. Infect. Chemother. 28, 1249\u20131254 (2022).","journal-title":"J. Infect. Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77768-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77768-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77768-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:03:08Z","timestamp":1730296988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77768-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77768"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77768-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"26064"}}